Reimagining Early Intervention: The Evolving Role of Wearable Cardioverter Defibrillators Powered by Zoll-Reimagining Early Intervention: The Evolving Role of Wearable Cardioverter Defibrillators Powered by Zoll

Reimagining Early Intervention: The Evolving Role of Wearable Cardioverter Defibrillators Powered by Zoll

Video Transcription

Video Summary

This roundtable discusses the evolving role of wearable cardioverter defibrillators (WCDs) in preventing sudden cardiac death (SCD). Experts highlight that SCD remains a significant global health issue, causing millions of deaths annually. The challenge lies in identifying those at risk since SCD arises from varied cardiac conditions. Early-phase risk after new diagnoses of ischemic or non-ischemic cardiomyopathy is notably high, as shown by the SCD PROTECT trial involving over 19,000 patients, revealing unexpected rates of life-saving WCD shocks.<br /><br />The panel emphasizes that the risk is dynamic, highest in the initial months while patients start and adjust heart failure medications. Permanent ICD implantation is often delayed due to this evolving risk and potential recovery of heart function. WCDs thus provide critical temporary protection during this vulnerable period. Compliance with wearing WCDs is crucial, and continuous patient engagement, education, and monitoring improve adherence and outcomes. The discussion also notes disparities in access and the need for better physician awareness and shared decision-making.<br /><br />Future opportunities include leveraging AI for risk stratification, expanding patient access, and integrating feedback mechanisms to improve device usage. The experts call for greater electrophysiologist involvement and further research to optimize WCD utilization and ultimately reduce SCD incidence.

Keywords

wearable cardioverter defibrillators

sudden cardiac death

risk stratification

ischemic cardiomyopathy

non-ischemic cardiomyopathy

heart failure medication

implantable cardioverter defibrillator

patient compliance